Literature DB >> 18713173

Antipsychotic use in the elderly: what doctors say they do, and what they do.

John Tiller1, David Ames, Henry Brodaty, Gerard Byrne, Sudarshan Chawla, Graeme Halliday, John Snowdon, Graham Hepworth, Peter McArdle, Isaac Schweitzer.   

Abstract

OBJECTIVE: To review psychiatrists' attitudes and actual practice on the use of typical and atypical antipsychotics in the elderly.
METHODS: Audit data were collected from 18-old-age psychiatry units across Australia. The attitudes of old age psychiatrists and their perceptions of the efficacy, tolerability and clinical usefulness of antipsychotics were examined.
RESULTS: The medications used for 321 patients were audited, and the attitudes of the 57 prescribing doctors were assessed. All available atypicals were prescribed and reported as more efficacious and clinically useful than typicals. Adverse events perceived by doctors as an obstacle to prescribing were more frequent than reported adverse event rates in product information. All diagnostic groups improved. Off-label use comprised almost 22% in this sample.
CONCLUSIONS: Adverse events are impediments to prescribing, more so with typical than atypical antipsychotics. All available atypicals were used and appeared effective in this elderly population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18713173     DOI: 10.1111/j.1741-6612.2008.00308.x

Source DB:  PubMed          Journal:  Australas J Ageing        ISSN: 1440-6381            Impact factor:   2.111


  3 in total

1.  Off-label use of atypical antipsychotics: cause for concern?

Authors:  Andrew McKean; Erik Monasterio
Journal:  CNS Drugs       Date:  2012-05-01       Impact factor: 5.749

Review 2.  Concerns about quetiapine.

Authors:  Jonathan Brett
Journal:  Aust Prescr       Date:  2015-06-01

3.  Stakeholders' views on the use of psychotropic medication in older people: a systematic review.

Authors:  Eliza Bednarczyk; Sarah Cook; Ruth Brauer; Sara Garfield
Journal:  Age Ageing       Date:  2022-03-01       Impact factor: 10.668

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.